Affiliate Senior Research Fellow of Institute for Molecular Bioscience
Institute for Molecular Bioscience
Associate Professor
School of Biomedical Sciences
Faculty of Health, Medicine and Behavioural Sciences
Availability:
Available for supervision
Media expert
Sebastian is an expert on molecular pharmacology of G protein-coupled receptors (GPCRs - the largest class of cell surface recpetors and major drug targets). His lab has a particular interest in those involved in communication between the gastrointestinal tract and brain (the so-called gut-brain axis). Current foccusses include ghrelin, melanocortin 4, dopamine D2, and cholecystokinin receptors and the lab has also worked on the calcitonin, glucagon-like peptide 1 and other receptors. His lab is interested in answering complelling biological questions relating to physiology and pathophysiology of the gut-brain axis all the way down to the level of the receptor.
Sebastian is from Adelaide and received his BSc(Hons) and PhD. from the University of Adelaide, where he worked on the Aryl Hydrocarbon receptor in the lab of Murray Whitelaw. He then did postdoctoral research on haematopoitic stem cell differentiation in Kelly McNagny’s lab at the Biomedical Research Centre at the University of British Columbia before joining Patrick Sexton to work on G protein-coupled receptors at Monash University .
Sebastian is now an ARC Future Fellow with his own research program in the School of Biomedical Sciences at the University of Queensland. He remains an adjunct member of MIPS DDB as well as CCeMMP.
Sebastian has honours and PhD positions for motivated students who have a strong desire to assume ownership of a project and work independently.
Affiliate of Centre for Innovation in Pain and Health Research (CIPHeR)
Centre for Innovation in Pain and Health Research
Faculty of Health, Medicine and Behavioural Sciences
Adjunct Senior Fellow
Australian Institute for Bioengineering and Nanotechnology
Availability:
Available for supervision
Media expert
I am a Research Fellow and Leader in Pain Relief Innovation at AIBN, UQ. My research interests sit at the interface of drug delivery and the pain field. My overarching research goal is to improve the quality of day to day life of patients suffering from chronic pain, by applying nanotechnology to the development of novel highly effective pain-killer products for improving chronic pain management. I am looking for highly motivated postgraduate students.
I also enjoy volunteering within the academic community, most notably as Head of the SBMS ECR Committee and Treasurer for The Queensland Chinese Association of Scientists and Engineers (QCASE). I am currently serving as guest editor of Pain Research and Management.and JoVE Methods Collection.
Research Interests
My research is focusing on nano-based drug formulation and development to improve chronic pain management. I have a broad and unique background in both pharmacology and drug delivery systems, with specific expertise in the development of novel drug products and testing their analgesic efficacy and safety including pharmacokinetic and pharmacodynamic studies. To date, I have established five different techniques to produce painkiller–loaded nanoparticles and nanofibers aimed at improving pain relief for patients where currently available pain-killers either lack efficacy or produce dose-limiting side-effects. For example, there is a small and very potent peptide that has been on the market as a chemical for over 10 years but which cannot be used as a therapeutic due to its short half-life and poor oral bioavailability. In the form of my nanoparticles, that peptide has the potential to become an oral treatment for improving pain management in patients whose pain is currently poorly alleviated by clinically used pain-killers. I have significant expertise in the use of rodent pain models to assess novel analgesics, and I have received excellent training in conducting research in accordance with the stringent requirements of the Quality Management System (quality accreditations (GLP and ISO17025) from NATA). Together, my knowledge, skills and experience will facilitate the efficient translation of my research from the bench to the clinic.
The current focus of the lab is on the development of drug-products to solve one of the largest unmet medical needs in the pain field through use of sustainable materials. 1) We are developing multifunctional sutures including biodegradable pain relief sutures. 2) We are developing my innovative novel nanoparticles, which deliver innate-immune targeting peptides for the treatment of cancer and cancer-related pain. We are establishing a platform for the development of safe, effective delivery for other small molecule peptide drugs in general to pave their way to clinical trials. 3) Our research also investigates the role of C5a and C3a, estrogen, etc. in the pathogenesis of chronic pain including neuropathic pain, cancer-related pain, low back pain and OA pain.
We work in collaboration with other leading Australian and international researchers to stay at the forefront of the drug delivery systems field and the pain field. We also provide preclinical evaluation of novel compounds and formulations.
Affiliate of Centre for Motor Neuron Disease Research
Centre for Motor Neuron Disease Research
Faculty of Health, Medicine and Behavioural Sciences
Senior Research Fellow
School of Biomedical Sciences
Faculty of Health, Medicine and Behavioural Sciences
Availability:
Available for supervision
Media expert
Dr Lee is a mid-career researcher with training in neuroscience, and additional experience in pharmacology and immunity. He completed his Ph.D. at the University of Queensland (UQ) in 2014 and continued his post-doctoral research studies in neuroinflammation and neurodegenerative diseases. He is currently a Senior Research Fellow and Group Leader at UQ's School of Biomedical Sciences, where he focusses on innate immune and inflammatory pathways including the complement system and inflammasomes in motor neuron disease (amyotrophic lateral sclerosis), Huntington’s disease, and Parkinson’s disease. Dr Lee’s research has demonstrated the therapeutic potential of multiple anti-inflammatory drugs targeting innate immune-mediated neuroinflammation to reduce neuronal cell death in animal models of neurodegenerative disease. He is also interested in the links between the immune system, stress response, and energy metabolism in neurodegeneration.
Australian Institute for Bioengineering and Nanotechnology
Availability:
Available for supervision
Over 5 years of experience in translational biomedical research, specialising in monoclonal antibody-based therapies, immuno-oncology, target discovery and theranostics in cancer. My main research focus is on targeted cancer therapies, understanding how target receptor endocytosis affects antibody drug conjugate (ADC) and radioligand therapy delivery, immune-mediated ADCC, and how combination therapies with immune checkpoint inhibitors can potentially improve therapeutic outcomes for patients.
Affiliate Postdoctoral Research Fellow of Frazer Institute
Frazer Institute
Faculty of Health, Medicine and Behavioural Sciences
Postdoctoral Research Fellow
Medical School
Faculty of Health, Medicine and Behavioural Sciences
Availability:
Available for supervision
Dr Moniruzzaman is working as a Senior Postdoctoral Research Fellow at the UQ Faculty of Medicine and PA Hospital of Metro South Health. His research focuses on the molecular pathobiology of inflammatory diseases, in particular, how mucosal epithelial cells and gut microbiota regulate immune function in the gastrointestinal (GI) tract and contribute to different diseases, including inflammatory bowel diseases (IBD) and functional GI symptoms called disorders of gut-brain interactions (DGBI). Dr Moniruzzaman received his PhD from The University of Queensland in 2020, where he studied how the interleukin(IL)-20 family of cytokines (IL-20, IL-22, and IL-24) regulate mucosal epithelial and immune function in inflammatory and infectious diseases, including ulcerative colitis (UC) and respiratory syncytial virus. After graduation, he received postdoctoral training in the IBD Lab at Mater Research Institute – UQ and Nanomedicine Lab at UQ School of Pharmacy, where he investigated the role of cannabinoid receptors in UC and colitis-associated colorectal cancer, development of cannabinoid formulations to treat UC, and involvement of autophagy gene Atg7 in 6-Thioguanin mediated protection from UC. He was awarded a highly competitive UQ Postdoctoral Research Fellowship (2021-2022) and UQ School of Pharmacy Strategic Grant (2022) to study cannabinoids and Atg7 in UC, Translational Research Institute LINC Grant (2023) to study cannabinoids in palliative care of patients with advanced cancer, and Metro South Health SERTA (2024-2025) to study non-antibiotic treatment of SI dysbiosis in patients with DGBI. His current work focuses on how small intestinal dysbiosis controls the mucosal immune microenvironment and contributes to the pathogenesis of DGBI, including irritable bowel syndrome (IBS), functional dyspepsia (FD), and gastroparesis.